Added benefit of the fixed combination of dapagliflozin and metformin is not proven
(Institute for Quality and Efficiency in Health Care) As was the case in dapagliflozin monotherapy, the drug manufacturer also presented no suitable data for the therapeutic indication in its dossier on the fixed combination with metformin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 15, 2014 Category: Global & Universal Source Type: news
Top medicine articles for March 2014
A collection of some interesting medical articles published recently:1 in 10 U.S. Children Now Has ADHD, CDC Says http://buff.ly/IeqY1SLifestyle interventions effectively decrease the incidence of type 2 diabetes in high-risk patients http://buff.ly/1bSrw9jTime for another go at understanding vitamin D metabolism http://buff.ly/1hdob8fDo healthier foods cost more than less healthy options? Healthy eating costs an extra $1.50 per day - BMJ http://buff.ly/JEpi2t1% of women in a U.S. study who have become pregnant claim to have done so as virgins - BMJ/Reuters http://buff.ly/19zkHIZYou’re never too old to exercise: 98-year-...
Source: Clinical Cases and Images - March 19, 2014 Category: Journals (General) Tags: Health News of the Day Source Type: news
AstraZeneca introduces combination drug Xigduo in UK for type 2 diabetes
AstraZeneca has launched its twice-daily tablet Xigduo (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) in the UK to treat patients with type 2 diabetes. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 12, 2014 Category: Pharmaceuticals Source Type: news
AstraZeneca and Bristol-Myers Squibb announce EU approval for diabetes drug Xigduo
The European Commission has granted marketing authorisation to AstraZeneca and Bristol-Myers Squibb's (BMS's) Xigduo (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) for the treatment of type 2 diabetes in the European … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 24, 2014 Category: Pharmaceuticals Source Type: news
First Approval for Flozin/Metformin Combo (Xigduo) in EUFirst Approval for Flozin/Metformin Combo (Xigduo) in EU
The first-ever approval of a combination product containing an SGLT2 inhibitor (dapagliflozin) together with metformin for type 2 diabetes has been approved in the EU. International Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 22, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
Farxiga (Dapagliflozin Film-coated Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 22, 2014 Category: Drugs & Pharmacology Source Type: news
FARXIGA™ (Dapagliflozin) Approved By U.S. DFA For Treatment Of Type 2 Adult Diabetes
AstraZeneca and Bristol-Myers Squibb Company have announced the U.S. Food and Drug Administration (FDA) approval of Farxiga in a press release featured in the Wall Street Journal. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - January 15, 2014 Category: Pharmaceuticals Source Type: news
FDA approves AstraZeneca and BMS' diabetes drug FARXIGA
The US Food and Drug Administration (FDA) has approved AstraZeneca and Bristol-Myers Squibb's (BMS) FARXIGA (dapagliflozin), a once-daily oral treatment for the improvement of glycaemic control in adults with type 2 diabetes mellitus. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 14, 2014 Category: Pharmaceuticals Source Type: news
FDA Approves Dapagliflozin for Type 2 Diabetes (FREE)
By Amy Orciari Herman
Dapagliflozin (Farxiga) — an inhibitor of sodium-glucose co-transporter 2 — has been approved as an adjunct to diet and exercise in adults with type 2 diabetes, the … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - January 9, 2014 Category: Primary Care Source Type: news
FDA Approves Dapagliflozin (Farxiga) for Type 2 Diabetes FDA Approves Dapagliflozin (Farxiga) for Type 2 Diabetes
The drug's approval comes after a prior rejection, and the FDA is now requiring several postmarketing safety studies. FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 8, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
FDA Approves New Diabetes Drug
WASHINGTON (MedPage Today) -- The FDA has approved dapagliflozin (Farxiga) for treatment of type 2 diabetes in adults, along with diet and exercise, the agency said in a statement. (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - January 8, 2014 Category: OBGYN Source Type: news
This Week in Endocrinology: Dapagliflozin Up for FDA OK
(MedPage Today) -- The FDA's impending decision on dapagliflozin for type 2 diabetes is likely to be the big story in endocrinology this week, but a study on a different way to treat acute kidney injury will also drive headlines. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - January 6, 2014 Category: Endocrinology Source Type: news
FDA Advisory Panel Recommends Approval of New Diabetes Drug (FREE)
By Amy Orciari Herman
FDA advisers voted 13 to 1 on Thursday to recommend approval of the diabetes drug dapagliflozin, Reuters reports. The drug's mechanism of action — inhibition of the sodium-glucose transporter in the kidneys — leads … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 16, 2013 Category: Primary Care Source Type: news
This Time, FDA Panel Endorses Diabetes Drug DapagliflozinThis Time, FDA Panel Endorses Diabetes Drug Dapagliflozin
New data from Bristol-Myers Squibb eased panel members' previous concerns about bladder cancer and liver toxicity enough to vote for dapagliflozin's approval, with the proviso that a postmarketing trial be completed. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 13, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
FDA Panel Likes Diabetes Drug on Second Try
(MedPage Today) -- An FDA advisory panel has voted 13-1 in favor of approval for dapagliflozin (Forxiga), a type 2 diabetes drug that the agency had turned down last year. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 13, 2013 Category: Cardiology Source Type: news
